GlassScriptPhysician profile
Benjamin David Harman
NPI 1245968197
$842.79
in general payments reported to CMS, 2019-2025
13 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.45 · 2023: $71.35 · 2024: $517 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $249.20 | 2024-2025 | Ingrezza |
| Abbott Laboratories | $131.69 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $110.59 | 2023-2024 | Veozah, Cresemba |
| Intuitive Surgical, INC. | $77.29 | 2025 | |
| Glaxosmithkline, LLC. | $74.52 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $49.05 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.39 | 2024-2025 | Jardiance |
| Pfizer INC. | $25.14 | 2024 | |
| Philips North America LLC | $19.91 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Ossur Americas, INC. | $17.45 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.40 | 2025 | Zoryve |
| Amgen INC. | $15.89 | 2023 | Otezla, Repatha |
| Lilly USA, LLC | $14.27 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Harman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.